Cargando…
Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19
The onset of the 2019 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic necessitated the identification of approved drugs to treat the disease, before the development, approval and widespread administration of suitable vaccines. To identify such a drug, we used a visual analytics...
Autores principales: | Smith, Daniel P., Oechsle, Olly, Rawling, Michael J., Savory, Ed, Lacoste, Alix M.B., Richardson, Peter John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356560/ https://www.ncbi.nlm.nih.gov/pubmed/34393789 http://dx.doi.org/10.3389/fphar.2021.709856 |
Ejemplares similares
-
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
por: Richardson, Peter, et al.
Publicado: (2020) -
A Repurposed Drug Screen Identifies Compounds That Inhibit the Binding of the COVID-19 Spike Protein to ACE2
por: Tsegay, Kaleb B., et al.
Publicado: (2021) -
On the Integration of In Silico Drug Design Methods for Drug Repurposing
por: March-Vila, Eric, et al.
Publicado: (2017) -
Current Status of Baricitinib as a Repurposed Therapy for COVID-19
por: Saber-Ayad, Maha, et al.
Publicado: (2021) -
Editorial: Drug Repurposing for COVID-19 Therapy
por: Maldonado, Rafael, et al.
Publicado: (2021)